Exact Sciences Corporation struggles with profitability due to high expenses. See why EXAS stock faces challenges despite the upcoming Cologuard Plus launch.

The in-vitro colorectal cancer screening tests market is set for significant growth, driven by advancements in diagnostics ...

The Assembly of First Nations says the ongoing postal strike is delaying supplies of medicine and other necessities in rural ...

Older adults on Medicare Advantage had improved adherence and odds of a test return when a stool test was mailed to them for ...

25 in JAMA Network Open. The kit, a fecal immunochemical test (FIT), uses antibodies to detect blood in stool. This blood is an early warning sign of colon cancer, and those who test positive are ...

In 1982, two Australian physician-scientists discovered a spiral-shaped bacterium whose form not only dictated function, but ...

Researchers sought to determine trends in participation and detection of CRC in multiround FIT-based CRC screening.

Discover the pros and cons of Shield, the FDA-approved cell-free DNA blood test for cancer detection shows false-positive ...

The average number of letters people receive has dropped significantly over the years — down to just two per week compared to ...

It’s an idea that thrills cancer researchers: a blood test that has the potential to screen for a sweeping number of cancers ...

In an indirect comparison study by researchers in Germany, a fecal immunochemical test showed similar sensitivity and specificity as Exact Sciences' Cologuard Plus test. Researchers developed an early ...